Xenon Pharmaceuticals Inc. $XENE Shares Sold by UBS Group AG

UBS Group AG cut its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 50.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 52,539 shares of the biopharmaceutical company’s stock after selling 54,205 shares during the quarter. UBS Group AG’s holdings in Xenon Pharmaceuticals were worth $2,355,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of XENE. Arizona State Retirement System boosted its position in Xenon Pharmaceuticals by 1.8% during the third quarter. Arizona State Retirement System now owns 19,290 shares of the biopharmaceutical company’s stock worth $774,000 after acquiring an additional 334 shares during the last quarter. Quarry LP boosted its position in Xenon Pharmaceuticals by 25.0% during the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 500 shares during the last quarter. Altfest L J & Co. Inc. boosted its position in Xenon Pharmaceuticals by 6.5% during the fourth quarter. Altfest L J & Co. Inc. now owns 8,232 shares of the biopharmaceutical company’s stock worth $369,000 after acquiring an additional 501 shares during the last quarter. State of Wyoming boosted its position in Xenon Pharmaceuticals by 112.8% during the third quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 610 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Royal Bank Of Canada raised their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, May 8th. Wedbush decreased their target price on shares of Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a research report on Monday, March 16th. Robert W. Baird raised their target price on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a research report on Monday, March 9th. Finally, Guggenheim restated a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $77.20.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, insider Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $156,706.77. Following the transaction, the insider owned 4,893 shares in the company, valued at $294,118.23. This trade represents a 34.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ian Mortimer sold 270,000 shares of Xenon Pharmaceuticals stock in a transaction on Monday, March 9th. The shares were sold at an average price of $60.33, for a total transaction of $16,289,100.00. Following the completion of the transaction, the chief executive officer owned 6,000 shares in the company, valued at approximately $361,980. This trade represents a 97.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 296,707 shares of company stock worth $17,845,365 in the last quarter. 4.07% of the stock is owned by insiders.

Xenon Pharmaceuticals Stock Down 0.1%

Shares of XENE opened at $53.90 on Thursday. The firm has a market cap of $5.21 billion, a PE ratio of -11.47 and a beta of 0.65. The company’s fifty day moving average is $56.04 and its two-hundred day moving average is $47.93. Xenon Pharmaceuticals Inc. has a fifty-two week low of $28.19 and a fifty-two week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same quarter last year, the business posted ($0.83) earnings per share. As a group, equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.88 earnings per share for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.